InVivo Therapeutics Holdings Corp. (NVIV) financial statements (2021 and earlier)

Company profile

Business Address ONE KENDALL SQUARE
CAMBRIDGE, MA 02139
State of Incorp. NV
Fiscal Year End December 31
SIC 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7171333201314
Cash and cash equivalents7171321201314
Short-term investments   12   
Restricted cash and investments00000  
Prepaid expense 0     
Other undisclosed current assets0010011
Total current assets:7171434211515
Noncurrent Assets
Operating lease, right-of-use asset1
Property, plant and equipment0001122
Prepaid expense1      
Restricted cash and investments00     
Other noncurrent assets0100000
Total noncurrent assets:3101122
TOTAL ASSETS:9181435221717
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2233122
Accounts payable1111111
Accrued liabilities1122011
Debt0000000
Derivative instruments and hedges, liabilities  0127 
Deferred revenue and credits000  
Total current liabilities:3235392
Noncurrent Liabilities
Long-term debt and lease obligation1 01122
Long-term debt, excluding current maturities  01122
Operating lease, liability1
Liabilities, other than long-term debt00000  
Deferred revenue and credits000  
Other liabilities000    
Total noncurrent liabilities:1011222
Total liabilities:42465114
Stockholders' equity
Stockholders' equity attributable to parent, including:616102917613
Common stock0000000
Additional paid in capital22522319418615010695
Accumulated deficit(219)(207)(184)(157)(134)(100) 
Other undisclosed stockholders' equity attributable to parent      (82)
Total stockholders' equity:616102917613
TOTAL LIABILITIES AND EQUITY:9181435221717

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Operating expenses(11)(13)(25)(24)(22)(18)(19)
Operating loss:(11)(13)(25)(24)(22)(18)(19)
Nonoperating income (expense)(0)(11)(2)1(11)(1)(39)
Investment income, nonoperating (12)   (0)(19)
Other nonoperating income (expense)(1)1(2)1(11)(1)(20)
Interest and debt expense  (0)(0)(0)(0)(0)
Loss before gain (loss) on sale of properties:(12)(23)(27)(24)(33)(19)(58)
Other undisclosed net income  0    
Net loss:(12)(23)(27)(24)(33)(19)(58)
Other undisclosed net income attributable to parent    0119
Net loss attributable to parent:(12)(23)(27)(24)(33)(18)(39)
Other undisclosed net income available to common stockholders, basic   0   
Net loss available to common stockholders, diluted:(12)(23)(27)(23)(33)(18)(39)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(12)(23)(27)(24)(33)(19)(58)
Comprehensive loss, net of tax, attributable to parent:(12)(23)(27)(24)(33)(19)(58)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: